Abstract | BACKGROUND:
Spinocerebellar ataxia type 3 is a rare neurodegenerative disease caused by a CAG repeat expansion in the ataxin-3 gene. Although no curative therapy is yet available, preclinical gene-silencing approaches to reduce polyglutamine ( polyQ) toxicity demonstrate promising results. In view of upcoming clinical trials, quantitative and easily accessible molecular markers are of critical importance as pharmacodynamic and particularly as target engagement markers. OBJECTIVE: We aimed at developing an ultrasensitive immunoassay to measure specifically polyQ-expanded ataxin-3 in plasma and cerebrospinal fluid (CSF). METHODS: Using the novel single molecule counting ataxin-3 immunoassay, we analyzed cross-sectional and longitudinal patient biomaterials. RESULTS: Statistical analyses revealed a correlation with clinical parameters and a stability of polyQ-expanded ataxin-3 during conversion from the pre-ataxic to the ataxic phases. CONCLUSIONS: The novel immunoassay is able to quantify polyQ-expanded ataxin-3 in plasma and CSF, whereas ataxin-3 levels in plasma correlate with disease severity. Longitudinal analyses demonstrated a high stability of polyQ-expanded ataxin-3 over a short period. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
|
Authors | Jeannette Hübener-Schmid, Kirsten Kuhlbrodt, Julien Peladan, Jennifer Faber, Magda M Santana, Holger Hengel, Heike Jacobi, Kathrin Reetz, Hector Garcia-Moreno, Mafalda Raposo, Judith van Gaalen, Jon Infante, Katharina M Steiner, Jeroen de Vries, Marcel M Verbeek, Paola Giunti, Luis Pereira de Almeida, Manuela Lima, Bart van de Warrenburg, Ludger Schöls, Thomas Klockgether, Matthis Synofzik, European Spinocerebellar Ataxia Type-3/Machado-Joseph Disease Initiative (ESMI) Study Group, Olaf Riess |
Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 36
Issue 11
Pg. 2675-2681
(11 2021)
ISSN: 1531-8257 [Electronic] United States |
PMID | 34397117
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
Chemical References |
- Peptides
- polyglutamine
- Ataxin-3
|
Topics |
- Ataxin-3
(genetics)
- Cross-Sectional Studies
- Humans
- Machado-Joseph Disease
(drug therapy, genetics)
- Neurodegenerative Diseases
- Peptides
|